Madison Muller

1 day ago | news.bloombergtax.com | Madison Muller |Robert Langreth |Ike Swetlitz

A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.

1 day ago | news.bloomberglaw.com | Madison Muller |Robert Langreth |Ike Swetlitz

A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.

1 day ago | bloomberg.com | Madison Muller |Robert Langreth |Ike Swetlitz

Wegovy and Zepbound have revolutionized the treatment of obesity.  (Bloomberg Businessweek) -- A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans.

1 week ago | bloomberg.com | Madison Muller

The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. A Super Bowl ad touting Hims & Hers Health Inc.'s copycat weight-loss drugs is getting pushback from the branded drugmakers' lobbying group, which says it's "misleading" and potentially violates marketing rules. Photographer: Gabby Jones/Bloomberg(Bloomberg) -- Hims & Hers Health Inc.

1 week ago | news.bloombergtax.com | Madison Muller

Hims & Hers Health Inc. is tapping former Amazon.com Inc. executive Nader Kabbani to be chief of operations as the telehealth company expands into new areas like blood testing. Kabbani led the acquisition of PillPack and the launch of Amazon Pharmacy during his nearly two decades at the e-commerce giant, before leaving in 2023 for stints at startups Flexport Inc. and Symbiotic Inc. He will replace Melissa Baird, who is stepping into an advisory role after more than seven years with Hims.